Pages

▼
Showing posts with label HCV. Show all posts
Showing posts with label HCV. Show all posts
Monday, April 27, 2015

Regulus Therapeutics RG-101 Continues to Have Potential in HCV Treatment Landscape

›
Having attended the International Liver Congress last week in Vienna, Austria, it has become clear to me that HCV is not going away soon...
10 comments:
Tuesday, April 7, 2015

Time is running out for Benitec

›
Benitec announced today that almost 1 ½ years after filing an IND for its DNA-directed RNAi HCV candidate, it has now obtained liver biop...
30 comments:
Monday, February 9, 2015

Simply Good: Regulus Therapeutics’ MicroRNA Inhibitor for HCV

›
Last year’s European Liver Meeting in London (EASL) was all about progress made in the treatment of HCV.  In addition to the expected buoy...
12 comments:
Sunday, February 1, 2015

Reading the Tea Leaves on Regulus Insider Sales

›
Revelations Friday night that the CEO ( here ) and CSO ( here ) of Regulus Therapeutics had sold sizeable amounts of Regulus stock just ...
20 comments:
Tuesday, January 20, 2015

RG-101 for HCV: Give Me 8mg/kg

›
Last October, Regulus Therapeutics announced stunning data from an ongoing trial of anti-miR122 RG-101 for the treatment of HCV infection...
17 comments:
Wednesday, October 22, 2014

Anti-MiR122 Therapeutic Stuns HCV World with Single-Dose Efficacy Results

›
This morning, Regulus Therapeutics greeted us with amazing results from a phase I study of RG-101, an anti-microRNA 122 oligo for the t...
23 comments:
Tuesday, October 21, 2014

Predicting the Outcome of Regulus HCV microRNA Therapeutics Study

›
Regulus Therapeutics is on track to reveal phase I results of its anti-HCV compound by the end of the year according to a presentation ...
4 comments:
Wednesday, October 23, 2013

Regulus Borrows from RNAi Delivery Technologies…5 Years Late

›
With the gift of birth of having access to all the technology toys from parent companies Alnylam and ISIS, Regulus Therapeutics in 2007 ...
5 comments:
Tuesday, May 7, 2013

Antisense Therapeutics Dressing Up with RNAi Delivery

›
The boundaries between RNAi Therapeutics and Antisense Therapeutics have become blurrier.  Originally, the basic practical difference bet...
4 comments:
Tuesday, October 4, 2011

Santaris Reports Clinical Efficacy of Anti-miR122 Treatment for HCV

›
Santaris reported yesterday intriguing antiviral HCV efficacy results from an ongoing phase IIa study of miravirsen, Santaris’ LNA-based an...
8 comments:
Thursday, February 25, 2010

GSK Dumps Santaris, Chooses Regulus

›
Patents still matter. An impressive demonstration late last year by Santaris and collaborators from a primate center in Texas was not enough...
12 comments:
Sunday, December 6, 2009

Anti-miR122 Antagomir Successful in Fighting HCV in Chimpanzees

›
I just wanted to post this video by KENS 5 on the anti-miR122 studies in HCV-infected chimpanzees by Danish LNA company Santaris and resea...
9 comments:
Sunday, July 6, 2008

The Potential for AAV-mediated RNAi Therapeutics

›
There is good reason to believe that synthetic siRNA-mediated RNAi Therapeutics should emerge as the most commonly used form of RNAi Therape...
5 comments:
Thursday, May 29, 2008

Santaris Initiates First Clinical Trial for a MicroRNA Therapeutic

›
Another notable milestone has been reached in the history of small RNA-based therapeutics. Yesterday, Santaris announced that it had comme...
4 comments:
Monday, October 29, 2007

Journal Club: A commonly used treatment for HCV, Interferon Beta, may largely act through microRNAs

›
While on vacation, an interesting study on the effect of interferon beta on microRNA levels was published in the journal Nature (Pedersen et...